Aptose Biosciences Inc. (TSX: APS)

Aptose Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Depreciation & Amortization	0.44	0.47	0.53	0.62	0.61	0.61
Depreciation & Amortization, Total	0.44	0.47	0.53	0.62	0.61	0.61
Loss (Gain) From Sale of Assets	0.01	-	0.02	-	-	-
Loss (Gain) From Sale of Investments	0	-	-	-	-	-
Stock-Based Compensation	2.59	3.65	5.21	12.95	21.44	2.3
Other Operating Activities	0.1	0.09	-0.02	7.52	0.09	0.39
Change in Accounts Payable	-3.1	-0.28	7.61	-0.47	0.21	0.65
Change in Other Net Operating Assets	2.07	2.69	-3.84	1.43	-1.01	0.77
Operating Cash Flow	-45.05	-44.59	-32.32	-43.3	-33.89	-21.56
Capital Expenditures	-0.03	-0.03	-0.02	-0.21	-0.08	-0.1
Sale of Property, Plant & Equipment	0	-	-	-	-	-
Investment in Securities	10.96	9.99	30.09	-35	12.71	-17.27
Investing Cash Flow	10.93	9.96	30.07	-35.21	12.63	-17.37
Issuance of Common Stock	18.71	6.91	0.12	0.23	58.98	103.89
Other Financing Activities	-	-	-	-	-0.17	-0.44
Financing Cash Flow	18.71	6.91	0.12	0.23	58.81	103.45
Foreign Exchange Rate Adjustments	-0	0	-0	0.01	0.01	0.02
Net Cash Flow	-15.42	-27.72	-2.14	-78.28	37.55	64.54
Free Cash Flow	-45.08	-44.62	-32.35	-43.52	-33.97	-21.66
Free Cash Flow Per Share	-5.31	-6.61	-5.26	-7.33	-6.23	-6.48
Levered Free Cash Flow	-27.67	-25.82	-16.6	-26.03	-13.14	-12.17
Unlevered Free Cash Flow	-27.67	-25.82	-16.6	-26.03	-13.14	-12.17
Change in Net Working Capital	0.66	-2.81	-4.32	-1.52	0.26	-1.81

Source: S&P Capital IQ. Standard template.